55 results about "Lipogenesis" patented technology

The present invention provides a novel method for inhibiting sugar-induced weight gain resulting from fructose and glucose driven lipogenesis. The method for inhibiting sugar-induced weight gain is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants to a host in need thereof. The present also includes novel methods for the prevention and treatment of diseases and conditions resulting from high carbohydrate ingestion. The method for preventing and treating these sugar-induced diseases and conditions is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants and a pharmaceutically acceptable carrier.

The present invention relates to a nutritional product, dietary supplement or pharmaceutical composition for the treatment of acne and related skin disorders. The invention also relates to a composition having a combination of ingredients such that it reduces symptoms associated with acne and related skin disorders. The invention relates to such a composition containing a variety of vitamins, minerals and one or more herbal medicine sources. In one preferred embodiment, the vitamins, minerals and one or more herbal medicine sources are present in an amount such that its mechanism of action is through inhibition of the growth of Propionobacterium acnes (P. acnes) and the inhibition of lipogenesis of sebum production. In another preferred embodiment, the invention contains a Vitamin A source to normalize keratinoid maturation, proliferation and turnover of skin cells. In another preferred embodiment, the invention further contains at least one of a Vitamin E source or Selenium. In another preferred embodiment, the invention further contains at least one of a Vitamin B6 source, a Pantothenic Acid source, Zinc or any active salt, and Chromium or any active salt. In another preferred embodiment, the invention further contains any one or more of an herbal source of Berberis aquifolium (Oregon grape root), Barberis vulgaris (barberry), Hydrastis Canadensis (goldenseal), or other herbal source of the compound berberine. The present invention also relates to a method of administering a therapeutically effective amount of the combination of ingredients for the treatment of acne and related skin disorders.

Optical methods and devices are provided for the reduction of the lipid content of adipocytes without significant heat or intolerable adverse effect on the cells and their surrounding tissues. The optical method and device can be used to irradiate adipose tissue through the skin with non-thermal and non-destructive effects by application of near infrared (NIR) irradiation at selected wave bands in selected ranges to affect modulation of innate enzymatic processes involved in lipolysis, lipogenesis, leptin secretion, adiponectin secretion, and / or glucose absorption.

Methods of culturing sebocyte cells, isolated populations of sebocytes, and methods of using the cultured sebocyte cells for screening compounds that inhibit or activate lipogenesis are provided.

The invention discloses a method for quickly detecting RFLP (restriction fragment length polymorphism) of SNP (single nucleotide polymorphism) of a common ox SIRT1 (silent information regulator 1) gene promotor region. The method comprises the following steps of: taking whole genome DNA (deoxyribonucleic acid) of common ox blood as a template and a primer pair P (F and R) as a primer; performing PCR (polymerase chain reaction) amplification on the common ox SIRT1 gene promotor region; digesting a PCR amplification product by using restriction endonuclease SmaI; performing agarose gel electrophoresis on segments after enzyme digestion; and identifying the SNP of the common ox SIRT1 promotor region according to a result of the agarose gel electrophoresis. Because important functions including muscle differentiation, lipogenesis and the like related to the SIRT1 are closely related to common ox meat quality characteristics, and the SNP can significantly affect the promotor activity of the SIRT1 gene and is related to various important economic characteristics of the common ox, the detection method provided by the invention lays a foundation for the establishment of the relationship between the SNP and growth characteristics of the SIRT1 gene, and can be used for marker assisted selection of the growth characteristics of the Chinese common ox so as to facilitate rapid establishment of common ox populations with excellent genetic resources.

The present invention provides a compound comprising a helminth-derived glycan and / or glycoconjugate thereof (e.g., a compound comprising a Lewisx antigen (e.g., LNFPIII), a non-Lewisx antigen (e.g., LNnT, LDN, and LDN derivatives), or a mixture of Lewisx and non-Lewisx antigens (e.g., SEA)), useful as a therapeutic compound for treating or preventing diseases associated with fat accumulation in the liver. The compounds of the invention are useful for treating or preventing the development of a fatty liver disease in a subject that has the disease or is at risk of developing the disease, and inhibiting lipogenesis in hepatocytes.; The invention also provides methods of regulating the Erk-c-fos / AP-1-FXRalpha signalling pathway by administering a compound comprising a helminth-derived glycan and / or glycoconjugate thereof to a subject with a fatty liver disease, or contacting a hepatocyte with a compound comprising a helminth-derived glycan and / or glycoconjugate thereof.

The invention belongs to the technical field of metal-organic frameworks, and discloses a ZIF-8 drug-loaded hydrogel osteogenesis-promoting scaffold, a preparation method and application, and the preparation method of the ZIF-8 drug-loaded hydrogel osteogenesis-promoting scaffold comprises the steps of construction of an SIM-ZIF-8 drug-loaded system and construction of the SIM-ZIF-8 / PEGDA / SA hydrogel. The novel ZIF-8 drug-loaded hydrogel osteogenesis-promoting scaffold is SIM-ZIF-8 / PEGDA / SA. According to the invention, an in-situ synthesis method is adopted to load SIM in a ZIF-8 pore structure (SIM-ZIF-8), and the biochemical microenvironment of bone tissues is improved, so that the dual effects of lowering lipid and forming bones are achieved. According to the invention, the ZIF-8 is loaded with an SIM small molecule drug for the first time, and the finally formed SIM-ZIF-8 system can reduce fat formation and promote osteogenesis under a high fat condition, and has a good application prospect in treatment of bone metabolic diseases caused by hyperlipidemia.

The invention discloses a fat management composition, a preparation method and an application. The fat management composition consists of the following components in parts by weight: 12-20 parts of L-carnitine, 11-20 parts of tea saponin, 5-11 parts of chitosan, 3-8 parts of anthocyanin, 1-3 parts of a bamboo leaf extract and 1-6 parts of limonin. The product (the fat management composition) provided by the invention, which is prepared from the L-carnitine, the tea saponin, the chitosan, the anthocyanin, the bamboo leaf extract and the limonin, has functions of promoting fat metabolism, improving a cell energy metabolic rate and inhibiting fat formation, and in addition, an effect of reducing weight can be also achieved; and the preparation method is simple and is beneficial for achievingindustrial production.

Intrauterine Fetal Growth Restriction (IUGR) is a very important clinical problem for which no satisfactory treatment is available so far. The current invention of intravenous (IV) hypertonic glucose supplementation to the mother to improve the glucose transfer to the fetus at the intervillous space by improved facilitated diffusion can be a safe and easy way of treating this problem, as the improved fetal blood glucose can lead to fetal lipogenesis that can conserve the fetal O2 (oxygen) utilization and also relieve the associated metabolic derangements of fetal hypoxia, hypercapnia, and acidosis, apart from replenishing the oxidized coenzymes needed for the carbohydrate metabolism. The use of trans-amniotic fetal feeding studied by animal experiments can be difficult in humans, because of the danger of infection, which can be overcome by the use of implantable ports with a sterile patch technique.

The invention relates to a compound serving as PPAR gamma ligand and the application thereof, and discovers that antibiotic ionomycin relates to novel ligand which can be bound with PPAR gamma with high affinity binding and specificity. The ligand has similar capability to traditional PPAR gamma activating agent, such as rogridone, on terms of restraining CDK5 to perform phosphorylation to PPAR gamma, has the property of adjusting blood sugar metabolic balance through PPAR gamma and further improving the low sensibility of II type diabetes insulin, and can better improve a series of iconic indexes of diabetes. In addition, ionomycin has low transcriptional activation capability and obviously lower side effects, such as lipogenesis and weight gain inducing, than that of rogridone-the ligand of PPAR gamma. The compound provides a three dimensional crystal structure of ionomycin and PPAR gamma which are mutually bound through X-ray crystal diffraction and reveals a special binding model of ionomycin in a PPAR gamma ligand binding domain at the atomic level, and the structure is obviously different from rogridone / PPAR gamma protein complex belonging to thiazolidinedione.

Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

The present invention provides a method for reducing the expressions of the sterol regulatory element-binding protein 1C (SREBP-1C), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase 1 (SCD-1), comprising administering to a subject a composition comprising an effective amount of a longan pericarp extract. The longan pericarp extract significantly inhibits lipogenesis, reduces the glutamic-pyruvic transaminase (GPT) index, and protects the liver.

The invention discloses a multi-drug combined rehabilitation granule for type 2 diabetes and application thereof. The multi-drug combined rehabilitation granule is formed by compounding of the following components by weight percentage: 45-90% of sorbitol, 5-50% of betaine or betaine hydrochloride, and 0.01-10% of Span-60. The sorbitol involved in the invention enables dissolved fat to form a stable emulsion or ultra microemulsion, with a molecular structure similar to that of glucose molecules, sorbitol can simulate glucose molecules to play a targeted positioning role, also has certain sweetness and can improve the taste of the granule; betaine / betaine hydrochloride is a biosurfactant, can assist dissolution of fat, also has liver protection function, and can improve the insulin utilization efficiency; and Span-60 can gradually dissolve fat deposited on a channel surface. The granule provided by the invention can make fat deposited on the surfaces of channels and semipermeable membranes form a stable "oil-in-water" emulsion or ultra microemulsion, deposited fat can be dissolved and then discharged out of the body through an excretory system, and the utilization efficiency of insulin can be improved.